Hyloris PharmaceuticalsLTS:0AB6 63 Days Inventory is 63.98 as of Dec. 2025, which is 28% above its 10-year median of 50.08. GuruFocus rates LTS:0AB6 with a GF Score™ of 63/100 and a GF Value™ of €9.56 (Possible Value Trap). The stock has 3 warning signs investors should review. Among 636 Biotechnology companies, Hyloris Pharmaceuticals ranks better than 75.94% on this metric.
If a company builds up inventory, it may mean it is having difficulties selling its goods.
Inventory Turnover measures how fast the company turns over its inventory within a year.
Hyloris Pharmaceuticals's Inventory Turnover for the
six
months ended in Dec. 2025 was 2.85.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Hyloris Pharmaceuticals's Inventory-to-Revenue for the
six
months ended in Dec. 2025 was 0.02.
Hyloris Pharmaceuticals (LTS:0AB6) Days Inventory Explanation
Days Inventory indicates the liquidity of the inventory. Generally, a lower Days Inventory is preferred as it indicates a shorter duration to clear off the inventory. An increase of the ratio may indicate the company's sales slowed. Similar ratios related to Days Inventory are:
1. Inventory Turnover measures how fast the company turns over its inventory within a year.
Hyloris Pharmaceuticals's Inventory Turnover for the
six
months ended in Dec. 2025 is calculated as
2. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Hyloris Pharmaceuticals's Inventory to Revenue for the
six
months ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
A lot of business are seasonable. It makes more sense to compare Days Inventory from the same period in the previous year instead of from the previous quarter.
Hyloris Pharmaceuticals Days Inventory Related Terms
Hyloris Pharmaceuticals Days Inventory Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LTS:0AB6 vs VRTX, REGN, ALNY: Days Inventory Comparison
For the Biotechnology subindustry, Hyloris Pharmaceuticals's Days Inventory, along with its competitors' market caps and Days Inventory data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Hyloris Pharmaceuticals Days Inventory vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Hyloris Pharmaceuticals's Days Inventory distribution charts can be found below:
* The bar in red indicates where Hyloris Pharmaceuticals's Days Inventory falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Hyloris Pharmaceuticals (LTS:0AB6) has a Days Inventory of 63.98 as of Dec. 2025. Days inventory represents the average amount of days a company holds inventory before selling it. View historical data on Hyloris Pharmaceuticals and its competitors. This is 28% above median its historical median of 50.08. Over the past decade, Hyloris Pharmaceuticals' Days Inventory has ranged from 50.08 to 84.75. According to the industry distribution chart, Hyloris Pharmaceuticals ranks #153 out of 636 companies in the Biotechnology industry, placing it in the top 24.1%.
Is Hyloris Pharmaceuticals' Days Inventory too high?
Hyloris Pharmaceuticals' current Days Inventory of 63.98 is 28% above median its 10-year median of 50.08. Over the past 10 years, this metric has ranged from a low of 50.08 to a high of 84.75. The Biotechnology industry median Days Inventory is 183.20. Hyloris Pharmaceuticals' value of 63.98 is 65.1% below this industry median. Based on the distribution chart, Hyloris Pharmaceuticals ranks #153 out of 636 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Hyloris Pharmaceuticals has a GF Score™ of 63/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Hyloris Pharmaceuticals' Days Inventory compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Hyloris Pharmaceuticals ranks #153 out of 636 companies for Days Inventory. This places Hyloris Pharmaceuticals in the top 24% of its industry — outperforming the majority of peers. The industry median Days Inventory is 183.20. Hyloris Pharmaceuticals' value of 63.98 is 65.1% below this benchmark. Historically, Hyloris Pharmaceuticals' own Days Inventory has ranged from 50.08 to 84.75 over the past decade. While the company's 10-year median is 50.08 vs. the industry median of 183.20, Hyloris Pharmaceuticals has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Inventory for a Biotechnology company?
The median Days Inventory among Biotechnology companies is 183.20, based on 636 companies in the industry. Companies in the top quartile (top 25%) have a Days Inventory significantly above this median, while those in the bottom quartile fall well below. However, Days Inventory should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Hyloris Pharmaceuticals's current Days Inventory of 63.98 is 65.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Inventory mean?
A high Days Inventory can signal that a stock is expensive relative to its fundamentals. Days inventory represents the average amount of days a company holds inventory before selling it. View historical data on Hyloris Pharmaceuticals and its competitors. For the Biotechnology industry, the median Days Inventory is 183.20 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Hyloris Pharmaceuticals's current Days Inventory is 63.98, which is 28% above median its own 10-year median of 50.08. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Hyloris Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Hyloris Pharmaceuticals (LTS:0AB6) is currently considered Possible Value Trap. The stock's GF Value™ is €9.56, compared to a current price of €4.53 — trading 52.6% below its estimated fair value. The current Days Inventory is 63.98, which is 28% above median its 10-year median of 50.08 and 65.1% below the Biotechnology industry median of 183.20. Hyloris Pharmaceuticals' overall GF Score™ is 63/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Inventory calculated?
Days Inventory is calculated from a company's financial statements. For Hyloris Pharmaceuticals (LTS:0AB6), the current Days Inventory is 63.98 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Hyloris Pharmaceuticals (LTS:0AB6) Overvalued in 2026?
Based on GuruFocus' analysis, Hyloris Pharmaceuticals stock appears to be undervalued.
The current stock price of €4.53 is trading 52.6% below its estimated GF Value™ of €9.56.
GuruFocus considers Hyloris Pharmaceuticals to be Possible Value Trap.
Key valuation signals for LTS:0AB6:
Days Inventory: 63.98 (28% above median its 10-year median of 50.08)
GF Value™: €9.56 vs. price of €4.53 (52.6% below fair value)
Industry Position: 65.1% below the Biotechnology median (#153 of 636)
No single metric tells the full story. See the LTS:0AB6 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Hyloris Pharmaceuticals SA is an early-stage specialty pharmaceutical company focused on adding value to the healthcare system by reformulating pharmaceuticals. The company develops proprietary products it believes offer advantages compared to available alternatives, to address the underserved medical needs of patients, hospitals, physicians, payors, and other stakeholders in the healthcare system. Its portfolio spans areas such as cardiovascular, other reformulations, and established markets (high-barrier generics). It has three early commercial-stage products, Sotalol IV for the treatment of atrial fibrillation, Podofilox Ge, and Maxigesic IV. Its revenue is mainly generated in the United States.
63GF Score
Get the complete analysis for LTS:0AB6
Days Inventory is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LTS:0AB6 has been successfully added to your 
